Abstract: This invention provides hexamethylenediamine muconate salt. This novel salt can be produced by bioconversion of toluene to muconic acid in the presence of hexamethylenediamine. Hydrogenation of this salt provides hexamethylenediamine adipate salt.

Abstract: Leads of an electronic component are formed in a Z-shaped configuration so as to provide a constant distance from the bottom surface of the body to the foot of the formed lead by a device having a lower floating anvil and complementary upper die unit, each of which have clamping and forming surfaces defining a Z-shaped joint therein between. The clamping surfaces are moveable relative to the forming surfaces of the anvil and the degree of movement which is permitted is controlled by preset sensing means responsive to contact with the body of the electronic component so as to produce the desired vertical distance between foot portion of the lead and the bottom surface of the component.

Abstract: 2-Amino-4-hydroxy-6-[2-(4-carboxyphenyl)alk-1-en-1-yl]pyrido[2,3,-d]pyrimid ines and 2-amino-4-hydroxy-6-[2-(4-carboxyphenyl)alk-1-yn-1-yl]pyrido[2,3-d]pyrimid ines are prepared through the reaction of a halo-aromatic compound and an unsaturated compound in the prosence of a palladium catalyst. The products are chemical intermediates for the preparation of antineo-plastic agents.A typical embodiment is the reaction of a protected 2-amino-4-hydroxy-6-ethynylpyrido[2,3-d]pyrimidine and an ester of 4-iodobenzoic acid.

Abstract: Pyrido[2,3-d]pyrimidine compounds are prepared through the reaction of 2,4-diamino-6(1H)-pyrimidone and an activated derivative of a dialdehyde. A typical embodiment utilizes the dinitrile.

Abstract: Derivatives of N-[2-(5,6,7,8-tetrahydropyrido-[2,3-d]pyrimidin-6-yl)-alkyl]benzoyl-L-glut amic acid are antineoplastic agents. A typical embodiment is N-(2-fluoro-4-[2-(2-amino-4-hydroxy-5,6,7,8-tetrahydropyrido-[2,3-d]pyrimi din-6-yl)ethyl]benzoyl)-L-glutamic acid.

Abstract: N-[4-{1-Hydroxy-3-(2-amino-4-hydroxy-5,6,7,8-tetrahydropyrido[2,3-d]pyrimid in-6-yl)prop-2-yl )benzoyl]-glutamic acid, it salts, and derivatives thereof, have an inhibitory effect on one or more enzymes which utilize folic acid and can be used, alone or in combination, to inhibit the growth of those neoplasms which otherwise depend upon the enzymes so inhibited. The compounds can be prepared through catalytic hydrogenation of a protected derivative of N-[4-{1-hydroxy-3-(2-amino-4-hydroxy-pyrido[2,3-d]pyrimidin-6-yl)prop-2-en -2-yl)benzoyl]glutamic acid and removal of the protecting groups.

Abstract: N-alkanoylglutamic acid derivatives in which the alkanoyl group is substituted with the 2-amino-4-hydroxy-5,6,7,8-tetrahydropyrido[2,3-d]pyrimidine-6-yl or 2,4-diamino-5,6,7,8-tetrahydropyrido[2,3-d]pyrimidin-6-yl group are antineoplastic agents. Typical embodiments are N-[6-(2-amino-4-hydroxy-5,6,7,8-tetrahydropyrido[2,3-d]pyrimidin-6-yl)hexa noyl]-L-glutamic acid and N-[4-{-(2-amino-4-hydroxy-5,6,7,8-tetrahydropyrido[2,3-d]pyrimidin-6-yl ethyl}cyclohex-1-yl]-L-glutamic acid.

Abstract: N-(Thienylcarbonyl)glutamic acid and N-(furylcarbonyl)glutamic acid derivatives in which the thienyl or furyl group is substituted with the 2-amino-4-hydroxy-5,6,7,8-tetrahydropyrido[2,3-d]pyrimidin-6-ylethyl or 2,4-diamino-5,6,7,8-tetrahydropyrido[2,3-d]-pyrimidin-6-ylethyl group are antineoplastic agents. Typical embodiments are N-[5-(2-{2-amino-4-hydroxy-5,6,7,8-tetrahydropyrido[2,3-d]pyrimidin-6-yl}e thyl)thien-2-ylcarbonyl]-L-glutamic acid and N-[5-(2-{2-amino-4-hydroxy-5,6,7,8-tetrahydropyrido[2,3-d]pyrimidin-6-yl}e thyl)fur-2-ylcarbony]-L-glutamic acid.

Abstract: The invention comprises a screening device for separating fine particles from a stream of air and a particulate mixture containing coarse and fines which includes a box-like hollow housing tilted downwardly at an acute angle. The housing contains a plurality of elongated screening elements and an air cleaning device consisting of a blowpipe and a series of nozzles directed at the screening elements through Venturi tubes. At periodic intervals a jet or pulse of air is injected into the Venturi tubes to reverse air flow and rid the screen elements of adhered coarse particles. Substantially complete fines removal can be achieved by employing a recycling loop between the coarse particle outlet and inlet of the housing.

Abstract: N-[N-(Tetrahydropyrido[2,3-d]pyrimidinylmethyl) aminomethylbenzoyl]glutamic acid derivatives are antineoplastic agents with an effect on one or more enzymes which utilize metabolic derivatives of folic acid. The compounds can be prepared by allowing a protected aminomethylbenzoylglutamic acid derivative to react with 2-amino-4-hydroxy-6-formylpyrido[2,3-d]pyrimidine, reducing the intermediate Schiff base, and subjecting the intermediate to catalytic hydrogenation. A typical embodiment is (S,S) N-[N-(2-amino-4-hydroxy-5,6,7,8- tetrahydropyrido-[2,3-d]pyrimidin-6-ylmethyl)-4-aminomethylbenzoyl]-glutam ic acid.

Abstract: Pyrimidin-5-yl derivatives of L-glutamic acid are anti-neoplastic agents. A typical embodiment is N-(4-[4-(2,4-diamino-6-hydroxypyrimidin-5-yl)-butyl]-benzoyl)-L-glutamic acid.

Abstract: This invention provides a process for the bioconversion of a non-growth aromatic feed to an accumulated quantity of a picolinic acid product with reduced accumulation of 2-hydroxymuconic semialdehyde, and conducted in the presence of ammonium or a primary amine, which acid subsequently can be converted by chemical means to a pyridine product.